Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ZIOPHARM Oncology Inc Announces Proposed Public Offering of Common Stock


Tuesday, 22 Oct 2013 04:03pm EDT 

ZIOPHARM Oncology Inc announced that it intends to commence an underwritten public offering of $50,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ZIOPHARM. J.P. Morgan Securities LLC will act as sole book-running manager for the proposed offering. ZIOPHARM intends to grant the underwriters a 30-day option to purchase up to $7,500,000 of additional shares. ZIOPHARM intends to use the net proceeds from the public offering for the overall development of its drug candidates, including its synthetic biology candidates and small molecule candidates, and for general corporate and working capital purposes. 

Company Quote

3.16
-0.1 -3.07%
25 Jul 2014